What is the purpose of this trial?
This study will evaluate the safety, tolerability and pharmacokinetic variability of atezolizumab, in combination with bevacizumab and/or Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) at the dose level and schedule indicated for hepatocellular carcinoma (HCC) (Arm A) and gastric cancer (Arm B), and in combination with nab-paclitaxel and gemcitabine at the dose level and schedule indicated for metastatic pancreatic cancer (Arm C).
Ages: 18 years and older
Dates: 06/28/2016 - 05/31/2019
Last Updated: 03/02/2017
Study HIC#: 1602017234